Isler, BurcuOzer, BernaCinar, GuleAslan, Abdullah TarikVatansever, CanselFalconer, CaitlinErgonul, Onder2024-07-052024-07-052022170934-97231435-437310.1007/s10096-022-04425-42-s2.0-85126797654https://doi.org/10.1007/s10096-022-04425-4https://hdl.handle.net/20.500.14411/1856Kapmaz, Mahir/0000-0002-4115-3914; DOGAN, OZLEM/0000-0002-6505-4582; Cinar, Gule/0000-0002-7635-8848; Vatansever, Cansel/0000-0003-3703-1882; Gönen, Mehmet/0000-0002-2483-075X; Chatfield, Mark D/0000-0002-0004-6274; Aydın, Mehtap/0000-0003-4044-9366; Tukenmez Tigen, Elif/0000-0003-2027-4116; Keske, Şiran/0000-0003-3823-4454; Ergonul, Onder/0000-0003-1935-9235; Kurt Azap, Özlem/0000-0002-3171-8926; can, fusun/0000-0001-9387-2526; balkan, ilker inanc/0000-0002-8977-5931; Azap, Alpay/0000-0001-5035-055X; Falconer, Caitlin/0000-0002-0476-7714A prospective, multicentre observational cohort study of carbapenem-resistant Klebsiella spp. (CRK) bloodstream infections was conducted in Turkey from June 2018 to June 2019. One hundred eighty-seven patients were recruited. Single OXA-48-like carbapenemases predominated (75%), followed by OXA-48-like/NDM coproducers (16%). OXA-232 constituted 31% of all OXA-48-like carbapenemases and was mainly carried on ST2096. Thirty-day mortality was 44% overall and 51% for ST2096. In the multivariate cox regression analysis, SOFA score and immunosuppression were significant predictors of 30-day mortality and ST2096 had a non-significant effect. All OXA-48-like producers remained susceptible to ceftazidime-avibactam.eninfo:eu-repo/semantics/closedAccessOXA-48OXA-232ST2096Klebsiella pneumoniaeCeftazidime-avibactamArticleQ2415841847WOS:00077020000000135301623